» Articles » PMID: 28970467

Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma

Overview
Journal Am J Case Rep
Specialty General Medicine
Date 2017 Oct 4
PMID 28970467
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Systemic mastocytosis with an associated hematologic non-mast cell lineage disease is a rare entity, and the majority of systemic mastocytosis cases are associated with myeloid neoplasm. Lymphoproliferative disorders are less commonly associated with systemic mastocytosis and a few cases of systemic mastocytosis associated with chronic lymphocytic leukemia have been described in the literature. CASE REPORT We present a case of indolent systemic mastocytosis associated with small lymphocytic lymphoma. The bone marrow biopsy demonstrated mast cells in the form of clusters and perivascular distribution on immunohistochemistry for tryptase, CD2, and CD25 markers. In addition, 30% involvement by small lymphocytic lymphoma was discovered in the form of interstitial lymphoid aggregates composed of small lymphocytes. Flow cytometry showed B-cells positively stained for CD19, CD20, CD5, CD23, and kappa light chains, and the CD38 expression was <5%. CONCLUSIONS In systemic mastocytosis with an associated hematologic non-mast cell lineage disease, the combination of systemic mastocytosis associated with small lymphocytic lymphoma is rare and the management strategy follows the principle of treating the two entities individually as if they are not related. Clinical surveillance is indicated for indolent systemic mastocytosis and low-risk small lymphocytic lymphoma to monitor for disease progression.

Citing Articles

Pancreatic neuroendocrine tumor presenting in indolent systemic mastocytosis: A case report.

Sacco K, Khan T, Passi M, Hernandez J, Komarow H Int J Surg Case Rep. 2020; 77:397-402.

PMID: 33220657 PMC: 7688994. DOI: 10.1016/j.ijscr.2020.11.028.

References
1.
Ma Y, Zeng S, Metcalfe D, Akin C, Dimitrijevic S, Butterfield J . The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002; 99(5):1741-4. DOI: 10.1182/blood.v99.5.1741. View

2.
Wang S, Hutchinson L, Tang G, Chen S, Miron P, Huh Y . Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013; 88(3):219-24. PMC: 4188390. DOI: 10.1002/ajh.23380. View

3.
Horny H, Sotlar K, Sperr W, Valent P . Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004; 57(6):604-8. PMC: 1770310. DOI: 10.1136/jcp.2003.014860. View

4.
Tefferi A, Vardiman J . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007; 22(1):14-22. DOI: 10.1038/sj.leu.2404955. View

5.
Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez M, Nunez R, Prados A . KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7):2366-72. DOI: 10.1182/blood-2006-04-015545. View